22/03/2017

XIII Cycle de Conférences – Sciences Biologiques

22 Mars 2017 – Au théâtre Lucio Costa – 20h00

The role of calreticulin in hematopoiesis

Maira DA COSTA CACEMIRO * PhD student in Hematology at Universidade de São Paulo (USP, Ribeirão Preto, Brazil) and at Institut Gustave Roussy (Villejuif – France). Scholarship: FAPESP

Myeloproliferative neoplasms (MPN) are hematological disorders characterized by increased proliferation and accumulation of mature myeloid cells in the bone morrow and peripheral blood. Patients with these disorders may present the JAK2V617F mutation which occurs in 95% of cases of polycythemia vera (PV) and 50% of cases of essential thrombocythemia (ET) and primary myelofibrosis (PMF). Recently a new mutation has been associated to MPN, this mutation occur on Calreticulin gene (CALR) and is present in 20%-30% of ET and PMF, but are generally absent in PV. Therefore, the aim of this project is to evaluate the role of CALR mutation on hematopoesis.

Role of regulatory immune cells in GVHD development or prevention after allogeneic HSCT in animal model of sickle cell disease

Júlia TEIXEIRA COTTAS DE AZEVEDO * PhD student in Immunology at Ribeirão Preto Medical School, University of São Paulo (USP, Ribeirão Preto, Brazil) and Paris Descartes University, France. Scholarship: Laboratory of Excellence GR-Ex – Paris Descartes University

Sickle cell disease (SDC) patients can be treated by the use of hydroxyurea and blood transfusions, but the allogeneic hematopoietic stem cell transplantation is the only curative option (HSCT). However, one important complication of HSCT is the development of Graft versus Host Disease (GVHD). Recent studies have demonstrated that iNKT cells execute an essential role in GVHD, but there are not studies evaluating the role of iNKT in the control GVHD development in SDC (patients and animals). Therefore, the objective of project is to study the function/interaction of different immune system cells (mainly iNKT, MDSC and Treg) and their role in GVHD development/prevention after HSCT in animal model of SCD.